TNFAIP2 and ovarian serous cystadenocarcinoma: Among them, TNFAIP2 was up-regulated in head and neck squamous cell carcinoma (HNSC), stomach adenocarcinoma (STAD), diffuse large B-cell lymphoma (DLBCL), glioblastoma multiforme (GBM), BLCA, AML, kidney renal clear cell carcinoma (KIRC), UCEC, kidney renal papillary cell carcinoma (KIRP), thymoma (THYM), CESC, cholangial carcinoma (CHOL), ovarian serous cystadenocarcinoma (OV), and pancreatic adenocarcinoma (PAAD) compared with corresponding normal counterpart.